Upload
delilah-alexander
View
221
Download
0
Embed Size (px)
Citation preview
The role of adjuvant TACE after curative
liver resection for HCCAnthony Fong
Prince of Wales Hospital
Hepatocellular Carcinoma
5th most common cancer in the world > 500,000 new cases per year 600,000 people die globally due to
HCC each year
1. Surgeon. 2005 Jun;3(3):210-5.The continuing challenge of hepatic cancer in Asia.Lai EC, Lau WY. J Am Coll Surg. 2007 Jul;205(1):27-36.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer J Clin 2005; 55: 74–108
Curative treatment for HCC
Surgical resection / transplantation Loco-regional ablation
Radiofrequency ablation Microwave ablation
Surgical resection
Poor survival rate despite curative resection 5-year survivals of 39% - 50%
High recurrence rate 1,3,5 years recurrence rate : 30.1%,
62.3%, 79% respectively
1. Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M, Broelsch CE.Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers.J Am Coll Surg. 2007 Jul;205(1):27-36.2. Dupont-Bierre E, Compagnon P, Raoul JL, Fayet G, de Lajarte-Thirouard AS, Boudjema K. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 2005; 201: 663–703. mamura H, Matsuyama Y, Tanaka E et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200–7.
Adjuvant Therapy
Adjuvant Therapy
Adjuvant therapy: TACE Systemic chemotherapy Immunotherapy Interferon Acyclic retinoid acid
TACETransArterial
ChemoEmbolization
TACE
Survival benefit in un-resectable HCC ? TACE as an adjuvant treatment
Llovet JM, Bruix JSystematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology 37:429, 2003
TACE as adjuvant therapy after curative liver
resection
TACE as adjuvant therapy Izumi R, Shimizu K, Iyobe T et al.
Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20: 295–301.
Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998; 133: 183–8.
Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Qian BY, Hao XS.Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases.Dig Surg. 2006;23(4):235-40.
Zhong C, Guo RP, Li JQ et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage IIIA hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135: 1437–45.
Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 2009; 198: 313–8.
TACE as adjuvant therapy
Patient selection – tumor extent Timing for TACE Chemotherapy agent Side effects
Patient selection for adjuvant TACE
TMN Staging for HCC T-staging
T1 - Solitary tumor without vascular invasion T2 - Solitary tumor with vascular invasion or multiple tumors none more
than 5 cm T3 - Multiple tumors more than 5 cm or tumor involving a major
branch of the portal or hepatic vein(s) T4 - Tumor(s) with direct invasion of adjacent organs other than the
gallbladder or with perforation of visceral peritoneum N-staging
N0 - Indicates no nodal involvement N1 - Indicates regional nodal involvement
M-staging M0 - Indicates no distant metastasis M1 - Indicates metastasis presence beyond the liver
Overall Staging
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage IIIA Stage IIIBStage IIIC
T3T4Tx
N0N0N1
M0M0M0
Stage IV Tx Nx M1
Author
Tumor extent
Sample size (Tx / Ctrl)
Median observation time (mths)
Disease free survival (Tx vs Ctrl)
Overall survival(Tx vs Ctrl)
Izumi(1994)
Vessel involvement / intrahepatic spreading
50 (23/27)
28.7 1 yr
64.5% vs 43%
1 yr
87% vs 81%
3 yr
32% vs 11.7%
3 yr
50.3% vs28.8%
Lai(1998)
Negative in Lipiodol CT, Angiography and USG 1 mth after OT
66 (30/36)
28.3 1 yr
50% vs 69% 3 yr
65% vs 67%
3 yr
18% vs 48%
Li(2006)
Solitary / Multiple tumor in one liver lobe
84 (39/45)
Not mentioned
1 yr
87.2% vs86.5%
Not stated
3 yr
60.7% vs47.8%
Zhong(2009)
Stage IIIa disease
118 (59/59)
20 1 yr
29.7% vs 14%
1 yr
80.7% vs56.5%
3 yr
9.3% vs 3.5%
3 yr
33.3% vs19.4%
Peng(2009)
HCC with PVTT (main or opposite branch <3 cm)
104 (51/53)
33.6 Not stated 1 yr
50.9% vs33.3%
3 yr
33.8% vs 17%
p = 0.0237 p = 0.5327
p = 0.04 p = 0.10
p = 0.004 p = 0.048
p = 0.0094
p = 0.345
Patient selection for adjuvant TACE
High risk tumor Tumor size (>5 cm) Vascular invasion Multiple tumor nodules
Timing for TACE
Timing for TACEAuthor Interval
between TACE and surgery
Number of courses
Outcome
Izumi (1994) 21-84 days 1 Improved DFS
Lai (1998) Both TACE and systemic chemoMean : 50 days
3 course of TACE 2 monthly8 doses of systemic chemo 6-weekly
Decreased DFS
Li (2006) 4 weeks 3 Course , 2 weekly
No sig. difference in DFS
Zhong (2009) 4-6 weeks 1 Improve DFS and OS
Peng (2009) 3-4 weeks, repeated once every 1-2 month
2-5 Improved OS
Timing for TACE
4 weeks after hepatectomy Single course already showed
survival benefit
Chemotherapy agent
Agent for TACE
Author TACE Agent Outcome
Izumi (1994) (20mg/m2) + Mitomycin C (10mg/m2), Lipiodol (3ml)
Improved DFS
Lai (1998) Systemic chemo : Epirubicin hydrochloride (40mg/m2)TACE : (10mg), Lipiodol (10ml)
Decreased DLS
Li (2006) (30mg), Mitomycin (20mg), . (80-100mg) / (400mg)
No sig. difference in DFS
Zhong (2009) (200mg/m2), Mitomycin (6mg/m2), Lipiodol (4-5ml), hydrocholride (40mg/m2)
Improve DFS and OS
Peng (2009) 5-FU (500mg/m2), (30mg/m2), Lipiodol (10-20ml)
Improved OS
Doxorubicin
Doxorubicin
Doxorubicin
Cisplatin
Cisplatin Carboplatin
CarboplatinEpirubicin
Agent for TACE
Doxorubicin (Adriamycin) / Epirubicin Mitomycin 5-FU Cisplatin / Carboplatin
Agents for TACE
Cleared rapidly by the liver. Large difference in concentration between the liver and systemic circulation
Effective primarily at high doses
Side effects
Author Side effects Serious side effects
Izumi (1994) Fever, nausea Hepatic injury required ICU care, Biloma
Lai (1998) Cellulitis Necrosis of lesser curve of stomach
Li (2006) Nausea and loss of appetite, impaired liver function, leukopenia and thrombocytopenia.
NIL
Zhong (2009) Nausea / Vomiting (50.9%), Increase ALT (29.8%), Pain (19%), Increase in bilirubin (19%), Leukopenia (1.8%)
NIL
Peng (2009) Fever (86%) , vomiting (66%), poor appetite (52%), Fatique (39%%)
NIL
Side effects
Fever Nausea / vomiting Impaired liver function Leukopenia Pain Local complications
Meta-analysis
Meta-analysis - Abstract
Our experience
Our experience
13 Patients underwent adjuvant TACE after liver resection of curative intent
Criteria of adjuvant TACE : Large tumor (>5 cm) Satellite nodules Vascular invasion Close surgical margin
Our experience
Follow up peroid
3-43 mths (median 15mths)
Tumor Size 1.5 – 14cm (Median 5.1cm)
Vascular invasion
61.5%
Surgical margin 0 - 5.8cm (Median 1cm)
Presence of multiple tumors
46%
Our experience
2 Patients had recurrence (15%) Both from lung metastasis Disease free survival : 3 mths / 15
mths 1 mortality from recurrence (Overall
survival 15mths)
Conclusion
Role of adjuvant TACE after curative liver resection is still controversial
Some trials showed promising results in patients with advanced disease
TACE is well tolerated in most studies Need further large scale study for
evaluation
Thank you